on FERMENTALG (EPA:FALG)
Fermentalg: 2025 Review and 2026 Outlook
Fermentalg closed 2025 with record revenue of €13.4 million, marking 17% growth thanks to the diversification of its markets. Operating income remained stable at -€9.5 million, with net income improving to -€9.4 million. This performance stems from a strengthened commercial diversification strategy and the development of new market segments, such as infant nutrition and aquaculture.
The company is supported by a €4 million loan from its partner Huvepharma, improving its cash position to €6.6 million. The upcoming launches of the EPA/DHA ΩRIGINS™ range and the Galdieria Blue colorant offer optimistic prospects. Fermentalg is targeting revenue of €20 million in 2026, based on the ongoing expansion of its BioSolutions portfolio.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all FERMENTALG news